Clinical Trial Update: A Study of BAY 43-9006 in Combination With Bicalutamide in Patients With Chemo-Naïve Hormone Refractory Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of sorafenib (BAY 43-9006) in combination with bicalutamide for chemo‑naïve hormone‑refractory prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Casodex (bicalutamide)
• Nexavar (Sorafenib)

Snippet

Sponsor: British Columbia Cancer Agency | Conditions: Adenocarcinoma of the Prostate | Phase 2 | Status: COMPLETED